Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients

Springer Science and Business Media LLC - Tập 34 Số 1 - 2022
mohammed saeed1, Alaa Hussein Mohamed2, Ahmed Hassan Owaynat3
1Critical Care Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
2Clinical Pharmacy Department, Helwan University Hospitals, Cairo, Egypt
3Nursing Department, Helwan University Hospitals, Cairo, Egypt

Tóm tắt

Abstract Background Coronavirus disease 2019 (COVID-19) causing severe acute respiratory distress syndrome caused by coronavirus 2 (SARS-CoV-2) still has no solid effective therapy. From previous studies, dexamethasone has led to a decrease in mortality in patients who required oxygen supplementation mainly invasive mechanical ventilation; at the same time, it is unknown if another corticosteroid can be effective when used and what is the optimal dose and its duration, to achieve improvement in clinical outcome. The cornerstone of the study was to compare the differences in clinical outcome and laboratory results in intensive care patients with SARS-CoV-2 pneumonia treated with dexamethasone 6 mg/day: doses versus those treated with methylprednisolone 2 mg/kg/day infusion. Materials and methods A prospective cohort study with a survival analysis of 414 patients diagnosed with severe COVID-19 pneumonia confirmed by polymerase chain reaction, for SARS-CoV-2 according to the Berlin definition of ARDS, who were admitted in the intensive care unit in the Helwan University Hospitals; the duration is from June 2020 till October 2021. Patients included in the study were mechanically ventilated with radiological confirmation of pneumonia by chest tomography; patients were included in the study according to the Berlin definition of ARDS and met the inclusion criteria of the study; 222 patients were treated with methylprednisolone infusion with a dose of 2 mg/kg/day versus 192 patients treated with dexamethasone 6 mg/day; both groups were treated for 10 days and were mechanically ventilated; the clinical out come and differences in the laboratory results were evaluated during the 10-day course for each group. Results Four hundred fourteen patients had COVID-19 pneumonia, diagnosed and confirmed by ground glass opacities in chest tomography and arterial partial pressure of oxygen/inspired oxygen and fraction of inspired oxygen (P/F ratio) less than 300. Two hundred twenty-two patients received methylprednisolone infusion at a dose of 2 mg/kg/day, and 192 patients received dexamethasone 6 mg daily; both groups were treated for 10 days. Inflammatory markers for cytokine storm were improved in the methylprednisolone group in comparison to the patients who were given dexamethasone when comparing the on-admission markers to the results of the inflammatory markers after 10 days, like ferritin after 10 days in methylprednisolone group 292.26 ± 330.10 versus the dexa group 648.10 ± 329.09 (p value < 0.001). D-dimer in the methylprednisolone group was 1301.75 ± 1515.51 versus 2523.78 ± 843.18 in the dexa group (p value < 0.001); CRP was 49.65 ± 19.91 in the methylprednisolone group versus 100.54 ± 36.75 (p value < 0.001) in the dexa group; LDH after 10 days in methylprednisolone group was 345.09 ± 128.31, and in the dexa group, it was 731.87 ± 195.09 (p value < 0.001); neutrophil to lymphocyte ratio (N:L ratio) after 10 days of treatment in the methylprednisolone group was 17.27 ± 5.09 versus 26.68 ± 7.19 (p value < 0.001) in the dexa group; also, the length of stay was shorter in the methylprednisolone group (7.33 ± 1.71) versus in the dexa group (19.43 ± 5.42) (p value < 0.001), together with mechanical ventilation MV days which are 3.82 ± 1.14 in the methyl group versus 16.57 ± 4.71 in the dexa group (p value < 0.001). Also, the radiological findings are improved in the methyl group (20.3%) versus the dexa group (73.4%) with p value < 0.001, and discharge from ICU in the methyl group was 79.7% versus 26.6% in the dexa group with p value < 0.001. Conclusions Treatment of severe COVID-19 pneumonia, Patients who were mechanically ventilated with methylprednisolone infusion 2 mg/kg/day for 10 days versus dexamethasone 6 mg for 10 days showed a statistically significant improvement in the MV days and length of stay in the intensive care unit, together with the overall mortality and severity inflammatory markers of cytokine storm c-reactive protein (CRP), D-dimer, ferritin, LDH, and N:L ratio.

Từ khóa


Tài liệu tham khảo

Eurosurveillance Editorial Team (2020) Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill 25(s):200131e. https://doi.org/10.2807/1560-7917.ES.2020.25.5.200131e

World Health Organization (2020). WHO announces COVID-19 outbreak a pandemic. Available from: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3who-announces-covid-19-outbreak-a-pandemic. Accessed 7 Dec 2020

World Health Organization (2020). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Available from: https://who.int/news/item/30–01–2020statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel–coronavirus-(2019-ncov). Accessed 11 Dec 2020

World Health Organization (2019). Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-COV) infection is suspected; interim guidance. Available from: https://apps.who.int/iris/handle/10665/178529. Accessed 3 Jan 2021

Worldmeter, COVID-19 Coronavirus Pandemic. 2020. J Availabe from: https://www.worldometers.Info/. Accessed 15 Jan 2021

Sabetian G, Moghadami M, HashemizadehFardHaghighi L, Shahriarirad R, Fallahi MJ, Asmarian N et al (2021) COVID-19 infection among healthcare workers: a cross-sectional study in southwest Iran. J 18(1):58. https://doi.org/10.1186/s12985-021-01532-0.

Lotfi M, Sefidbakht S, Moghadami M, Iranpour P, Emami Y, Jafari SH, et al (2020) Introduction of a radiologic severity index for the 2019 novel coronavirus (COVID-19). https://doi.org/10.21203/rs.3.rs-47641/v1

Shahriarirad R, Sarkari B (2020) COVID-19: clinical or laboratory diagnosis? A matter of debate Trop Dr 51(1):131–132. https://doi.org/10.1177/0049475520945446

Ashraf MA, Keshavarz P, Hosseinpour P, Erfani A, Roshanshad A, Pourdast A, et al (2020) Coronavirus disease 2019 (COVID-19): a systematic review of https://bmcifectdis.biomedcentral.com/articles/10.1186/s12879-021-06045-3. Prengnacy and the possibility of vertical transmission. J. Reprod Infertil 21(3):157–68

Mirahmadizadeh A, Ranjbar K, Shahriarirad R, Erfani A, Ghaem H, Jafari K et al (2020) Evaluation of students attitude and emotions towards the sudden closure of schools during the COVID-19 pandemic: a cross-sectional study. BMC Psychol 8(1):1–7. https://doi.org/10.1186/s40359-020-020-00500-7

Shahriarirad R, Erfani A, Ranjbar K, Bazrafshan A, Mirahmadizadeh A (2021) The mental health impact of COVID-19 outbreak: a Nationwide survey in Iran. Int J Ment Health Syst 15(i):19. https://doi.org/10.1186/s13033-021-00445-3

Erfani A, Shahriarirad R, Ranjbar K, Mirahmadizadeh A, Moghadami M. Knowledge, attitude and practice toward the novel coronavirus (COVID-19) outbreak: a population- based survey in Iran. Bull World Health Organ. 2020. https://doi.org/10.2471/BLT.20.256651

Cheng ZJ, Shan J (2020) 2019 novel coronavirus: where we are and what we know published correction appears in infection. Infection 48(2):i55-63. https://doi.org/10.1007/S15010-020=01401-y

Young B, Tan TT, Leo YS (2021) The place for remdesivir in COVID-19 treatment. Lancet Infect Dis 21(l):20–l. https://doi.org/10.1016/S1473-3099(20)30911-7

Vetter P, Kaiser L, Calmy A, Agoritsas T, Huttner A (2020) Dexamethasone and remdesivir: finding method in the COVID-19 madness. Lancet Microbe 1(8):e309-10. https://doi.org/10.1016/S2666-5247(20)30173-7

Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y et al (2020) Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the south of Iran. BMC Infect Dis 20(1):1–12. https://doi.org/10.1186/s12879-020-05128-x

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Mehta P, McAuley Dt, Brown M, Sanchez K, Tattersall RS, Manson JI et al (2020) COVlD-19: consider cytokine storm syndromes and immuno-suppression. Lancet 395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0

Stockman IJ, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3(9):e 343. https://doi.org/10.1371/journal.pmed.0030343

Arabi YM, Mandourah Y, Al-Hameed F et al (2018) Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197(6):757–767. https://doi.org/10.1164/rccm.201706-l1720C

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al (2021) Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384(8):693–704. https://doi.org/10.1056/NEJM0a2021436

Williams DM (2018) Clinical pharmacology of corticosteroids. Respir Care 63(6):655–70. https://doi.org/10.4187/respcare.o6314

Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D et al (2020) WHO rapid evidence appraisal for COVID-19 Therapies (REACT) working group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a metaanalysis. JAMA 324(13):1330–41. https://doi.org/10.1001/jama.2020.17023

Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J et al (2017) Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Crticial Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 43(12):1781–1792. https://doi.org/10.1007/S00134-017-1914-x

Hui DS, Sung JJ (2003) Severe acute respiratory syndrome. Chest 124(1):12–5. https://doi.org/10.1378/chest.124.1.12

Papamanoli A, Yoo J, Grewal P, Predun W, Hotelling J, Jacob R, et al (2020) High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. Eur J Clin Investig:e13458. https://doi.org/10.1111/eci.13458

COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 1 Aug 2020

Association WM (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 3l0(20):2191–4. https://doi.org/10.1001/jama.2013.281053

Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ (2018) Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care 6(1):53. https://doi.org/10.1186/s40560-018-9321-9

Braude AC, Rebuck AS (1983) Prednisone and methylprednisolone disposition in the lung. Lancet 2(8357):995–997. https://doi.org/10.1016/s0140-6736(83)90981-9

Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P et al (2020) COVID-19 management task force Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 71(16):2114–20. https://doi.org/10.1093/cid/ciaa601

Alzghari SK, VSJJoCV A (2020) Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 127:104380 (32353761)

Salvi R, Patankar P (2020) Emerging pharmacotherapies for COVID-19. Biomed Pharmacother 128:110267. https://doi.org/10.1016/j.biopha.2020.110267

Darwish I, Mubareka S, Liles WC (2011) Immunomodulatory therapy for severe influenza. Expert Rev Anti-Infect Ther 9(7):807–822. https://doi.org/10.1586/eri.11.56

Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen LW (2020) Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med 48(2):e98–e106. https://doi.org/10.1097/CCM.0000000000000004093

Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S et al (2020) Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomized controlled clinical trial. Eur Respir J 56(6):2002808. https://doi.org/10.1183/1399300302808-2020

Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P et al (2020) A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther 5(1):57. https://doi.org/10.1038/S41392-020-0158-2

Corral L, Bahamonde A, de las Revillas FA, Gomez-Barquero J, Abadia-Otero J, Garcia- Ibarbia C, et al (2020) GLUCOCOV1D: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv. https://doi.org/10.1101/2020.06.17.2013357-9

Jeronimo CMP, Farias MEL Val FFA, Sampaio VS, Alexandre MAA, Melo GC et al (2020) Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis:ciaa1177. https://doi.org/10.1093/cid/ciaa1177

Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, et al (2020) Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19. Clin Infect Dis:ciaan63. https://doi.org/10.1093/cid/ciaa1163

Braude A, Rebuck AJTL (1983) Prednisone and methylprednisolone disposition in the lung. Lancet 2(8357):995–997. https://doi.org/10.1016/s0140-6736(83)90981-9

Hirano T, Homma M, Oka K, Tsushima H, Niitsuma T, Hayashi TJI (1998) Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids. Immunopharmacology 40(1):57–66. https://doi.org/10.1016/s0162-3109(98)00025-3

Vichyanond P, Irvin CG, Larsen GL, Szefler SJ, MRJJoa H (1989) Immunology C. Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol 84(6 Pt 1):1867–73. https://doi.org/10.1016/0091-6749(89)90381-3

Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ (2003) Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 43(11):1216–27. https://doi.org/10.1177/0091270003258651

Yang R, Xiong Y, Ke H, Chen T, Gao S (2020) The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19. Eur J Clin Invest 50(11):e13412 Epub 2020 Oct 2. pmid: 32954492. View Article • Pub.Med/NCBI • Google Scholar

Ruiz-Irastorza Guillermo, Pijoan Jose-lgnacio, Bereciartua Elena, Susanna Dunder, Jokin Dominguez et al (2020) Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: an observational comparative study using routine care data. PLoS One 15(9):e0239401 Published online 2020 Sep 22. pmid: 32960899. View Article PubMed/NCBI Google Scholar

The Islamic Republic of Iran Medical Council (2020) Guide to diagnosis and treatment of COVID-19. Available from: https://irimc.org/news/id/45316. Accessed 10 Aug 2020

World Health Organization (2020) WHO R&D Blueprint-Novel Coronavirus COVID-19 Therapeutic Trial Synopsis Available from: https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 34 Số 1

Thông tin tác giả